

## COVID-19 Information

[Public health information \(CDC\)](#)

[Research information \(NIH\)](#)

[SARS-CoV-2 data \(NCBI\)](#)

[Prevention and treatment information \(HHS\)](#)

[Español](#)

Try the modernized [ClinicalTrials.gov beta](#) website. Learn more about the [modernization effort](#).

 U.S. National Library of Medicine

*ClinicalTrials.gov*



## Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO) (GALILEO)



The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our [disclaimer](#) for details.

ClinicalTrials.gov Identifier: NCT01012973

[Recruitment Status](#) ⓘ : Completed

[First Posted](#) ⓘ : November 13, 2009

[Results First Posted](#) ⓘ : November 22, 2012

[Last Update Posted](#) ⓘ : November 2, 2014

**Sponsor:**

Bayer

Mylan v. Regeneron  
IPR2021-00880  
U.S. Pat. 9,669,069  
Exhibit 2127

Regeneron Pharmaceuticals

**Information provided by (Responsible Party):**

Bayer

[Study Details](#)[Tabular View](#)[Study Results](#)[Disclaimer](#)[How to Read a Study Record](#)**Study Description**Go to **Brief Summary:**

To determine the efficacy of vascular endothelial growth factor (VEGF) Trap-Eye injected into the eye on vision function in subjects with macular edema as a consequence of central retinal vein occlusion

<u>Condition or disease</u> ⓘ	<u>Intervention/treatment</u> ⓘ	<u>Phase</u> ⓘ
Retinal Vein Occlusion	Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) Other: Sham treatment	Phase 3

**Study Design**Go to **Study Type** ⓘ :

Interventional (Clinical Trial)

**Actual Enrollment** ⓘ :

177 participants

**Allocation:**

Randomized

**Intervention Model:**

Parallel Assignment

**Masking:**

Triple (Participant, Investigator, Outcomes Assessor)

**Primary Purpose:**

Treatment

**Official Title:**

A Randomized, Double-masked, Sham-controlled Phase 3 Study of the Efficacy, Safety and Tolerability of Repeated Intravitreal Administration of VEGF Trap-Eye in Subjects With Macular Edema Secondary to

**Study Start Date** ⓘ :

October 2009

**Actual Primary Completion Date** ⓘ :



February 2011

**Actual Study Completion Date** ⓘ :

February 2012

**Resource links provided by the National Library of Medicine**[MedlinePlus](#) related topics: [Edema](#)[Drug Information](#) available for: [Aflibercept](#) [Ziv-aflibercept](#)[U.S. FDA Resources](#)**Arms and Interventions**Go to 

<a href="#">Arm</a> ⓘ	<a href="#">Intervention/treatment</a> ⓘ
<p>Experimental: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)</p> <p>Participants received a 2 mg dose of Intravitreal Aflibercept Injection (IAI) administered every 4 weeks from Day 1 through Week 20, later as often as every 4 weeks depending on the study retreatment criteria from Week 24 through Week 48. Follow-up phase: Participants on IAI, who continued the study, received 2 mg dose of IAI depending on the study retreatment criteria at Week 60 and 68.</p>	<p>Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)</p> <p>Intravitreal injection. Weeks 0 to 20 of Aflibercept Injection every 4 weeks; Weeks 24 to 52 every 4 weeks PRN (pro re nata, on demand); plus additional on Week 60 and 68.</p> <p>Other: Sham treatment</p> <p>Sham treatment. Weeks 0 to 52 sham treatment every 4 weeks; plus additional on Week 60 and 68.</p>

Arm 	Intervention/treatment 
<p>Sham Comparator: Sham treatment</p> <p>Participants received sham treatment administered every 4 weeks from Day 1 through Week 52. Follow-up phase: Participants on sham treatment, who switched to Intravitreal Aflibercept Injection (IAI), received a 2 mg dose of IAI at week 52 and depending on the study retreatment criteria at Week 60 and 68.</p>	<p>Other: Sham treatment</p> <p>Sham treatment. Weeks 0 to 52 sham treatment every 4 weeks; plus additional on Week 60 and 68.</p>

## Outcome Measures

Go to

### Primary Outcome Measures :

1. Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 24 With Discontinued Participants Before Week 24 Evaluated as Failures [ Time Frame: Baseline and Week 24 ]

Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 24 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.

### Secondary Outcome Measures :

1. Change From Baseline in BCVA as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 24 - Last Observation Carried Forward (LOCF) [ Time Frame: Baseline and Week 24 ]

Defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 24 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning. However, because this was assessed at the screening visit, subjects may have had a higher BCVA recorded at the baseline visit and would not have been excluded from the study.

2. Change From Baseline in Central Retinal Thickness (CRT) at Week 24 - LOCF [ Time Frame: Baseline and Week 24 ]
3. Percentage of Participants Who Developed Neovascularization During the First 24 Weeks [ Time Frame: From baseline until Week 24 ]

Formation of blood vessels in the anterior segment, optic disc, or elsewhere in the fundus up to Week 24

4. Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score at Week 24 - LOCF [ Time Frame: Baseline and Week 24 ]

The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales which are all scored from 0-100. To reach the overall composite score, each sub-scale score is averaged in order to give each sub-scale equal weight

5. Change From Baseline in European Five-dimensional Health Scale (EQ-5D) Score at Week 24 - LOCF [ Time Frame: Baseline and Week 24 ]

EQ-5D is a quality of life questionnaire based on a scale from -0.594 (worst) to 1.00 (best).

## Eligibility Criteria

Go to

### Information from the National Library of Medicine



*Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, [Learn About Clinical Studies](#).*

### Ages Eligible for Study:

18 Years and older (Adult, Older Adult)

### Sexes Eligible for Study:

All

### Accepts Healthy Volunteers:

No

### Criteria

Inclusion Criteria:

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.